These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25130822)

  • 21. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
    Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
    Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
    Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.
    Cermák J
    Hemoglobin; 2006; 30(1):105-12. PubMed ID: 16540422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study of abnormal iron metabolism parameters and iron overload in patients with myelodysplastic syndromes].
    Song LL; Zheng QQ; Xiao C; Guo J; Wu D; Su JY; Zhou LY; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):903-907. PubMed ID: 27801326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
    Cermak J; Jonasova A; Vondrakova J; Walterova L; Hochova I; Siskova M; Neuwirtova R
    Hemoglobin; 2011; 35(3):217-27. PubMed ID: 21599434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of repeated blood donations on the iron status of Iranian blood donors attending the Iranian blood transfusion organization.
    Djalali M; Neyestani TR; Bateni J; Siassi F
    Int J Vitam Nutr Res; 2006 May; 76(3):132-7. PubMed ID: 17048192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
    Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
    Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivity of patients with maintenance hemodialysis to erythropoietin in the treatment of renal anemia.
    Hu JP; Cheng X; Xu XF; Yu GJ; Luo F; Zhang GS; Yang N; Shen P; Yan XY
    J Biol Regul Homeost Agents; 2016; 30(2):535-40. PubMed ID: 27358145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study of iron overload assessment by T2* magnetic resonance imaging in patients with myelodysplastic syndromes].
    Song LL; Lu HY; Xiao C; Wu LY; Wu D; Su JY; Zhou LY; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):222-226. PubMed ID: 30929390
    [No Abstract]   [Full Text] [Related]  

  • 32. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
    Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
    Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
    [No Abstract]   [Full Text] [Related]  

  • 34. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
    Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
    Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influencing factors of iron metabolism assessment in patients with myelodysplastic syndrome: A retrospective study].
    Zhang Y; Xiao C; Li J; Song LX; Zhao YS; Zhao JG; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):293-299. PubMed ID: 35680627
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes.
    Piedras J; Hernández G; López-Karpovitch X
    Am J Hematol; 1998 Feb; 57(2):113-8. PubMed ID: 9462542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of iron chelation therapy for patients with myelodysplastic syndromes.
    Steensma DP
    J Natl Compr Canc Netw; 2011 Jan; 9(1):65-75. PubMed ID: 21233245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anemia in kidney transplants without erythropoietic agents: levels of erythropoietin and iron parameters.
    Florit EA; Hadad F; Rodriguez Cubillo B; De la Flor JC; Valga F; Perez Flores I; Calvo Romero N; Valero San Cecilio R; Barrientos Guzman A; Sanchez Fructuoso A
    Transplant Proc; 2012 Nov; 44(9):2590-2. PubMed ID: 23146464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.